ABOUT WUXI BIOLOGICS

WuXi Biologics is a leading CRDMO providing integrated research, development, and manufacturing services. Our end-to-end model brings biologics and vaccines to patients worldwide with unmatched speed and reliability, eliminating risky vendor-to-vendor handoffs. Flexible standalone CMC services fill critical program gaps for tailored support at any stage.

Multi-modality discovery capabilities generate development-ready assets with a clear through-line to GMP manufacturing. With mammalian and microbial expression systems, alongside subsidiaries WuXi XDC and WuXi Vaccines, we support modalities from monoclonal and bispecific antibodies to antibody-drug conjugates. Technical innovation across cell line development, bioprocessing, and formulation unlocks high yields, purity, and stability with maximum efficiency.

Our global network spans 6 countries, bringing services closer to clients. Operations harmonized under one quality system join a strong regulatory track record to support programs of all sizes.

INDUSTRY INSIGHTS

CONTACT INFORMATION

WuXi Biologics

7 Clarke Drive

Cranbury, NJ 08512

UNITED STATES

HEADQUARTERS

WuXi Biologics China HQ
108 Meiliang Road, Mashan, Binhu District, Wuxi Jiangsu, China, 214092

SOLUTIONS

  • Recent studies offer insights on formulation, device compatibility, stability testing, and fill‑finish optimization — helping teams boost product performance and cut development risk.

  • Learn how integrated R&D and manufacturing streamline the journey from discovery to large-scale production, helping teams advance biologics faster and with greater confidence.

  • See how coordinated development — from DNA construct through IND submission —helps teams streamline decision‑making, strengthen data continuity, and prepare more confidently for early clinical milestones.